{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:36Z","timestamp":1791347316197,"version":"4.3.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T00:00:00Z","timestamp":1322006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00228-011-1166-5","type":"journal-article","created":{"date-parts":[[2011,11,22]],"date-time":"2011-11-22T07:16:54Z","timestamp":1321946214000},"page":"689-695","source":"Crossref","is-referenced-by-count":46,"title":["The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis"],"prefix":"10.1007","volume":"68","author":[{"given":"Tanuja N.","family":"Gengiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas H. G.","family":"Holford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Abdool Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,23]]},"reference":[{"key":"1166_CR1","unstructured":"World Health Organization (2008) Global tuberculosis control: surveillance planning financing. WHO, Geneva"},{"issue":"1","key":"1166_CR2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002030-200201040-00010","volume":"16","author":"GL Dean","year":"2002","unstructured":"Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16(1):75\u201383","journal-title":"AIDS"},{"key":"1166_CR3","doi-asserted-by":"crossref","unstructured":"Gengiah TN, Gray AL, Naidoo K, Karim QA (2011) Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf 10:559\u2013574. doi: 10.1517\/14740338.2011.546783","DOI":"10.1517\/14740338.2011.546783"},{"issue":"9","key":"1166_CR4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","volume":"162","author":"CK Finch","year":"2002","unstructured":"Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interactions: an update. Arch Intern Med 162(9):985\u2013992","journal-title":"Arch Intern Med"},{"issue":"2","key":"1166_CR5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","volume":"45","author":"Z Desta","year":"2001","unstructured":"Desta Z, Soukhova NV, Flockhart DA (2001) Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 45(2):382\u2013392. doi: 10.1128\/AAC.45.2.382-392.2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1166_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","volume":"72","author":"S Mouly","year":"2002","unstructured":"Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72(1):1\u20139. doi: 10.1067\/mcp.2002.124519","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1166_CR7","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","volume":"38","author":"ET Ogburn","year":"2010","unstructured":"Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z (2010) Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38(7):1218\u20131229. doi: 10.1124\/dmd.109.031393","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1166_CR8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/00003088-200140120-00002","volume":"40","author":"PF Smith","year":"2001","unstructured":"Smith PF, DiCenzo R, Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40(12):893\u2013905","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1166_CR9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1):71\u201375","journal-title":"AIDS"},{"issue":"9","key":"1166_CR10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","volume":"41","author":"LF Lopez-Cortes","year":"2002","unstructured":"Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, Sarasanacenta M, Lopez-Pua Y, Pachon J (2002) Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 41(9):681\u2013690","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1166_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/157016207780636588","volume":"5","author":"A Matteelli","year":"2007","unstructured":"Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC, Caligaris S, Tomasoni L, Manfrin M, Capone S, Carosi G (2007) Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 5(3):349\u2013353","journal-title":"Curr HIV Res"},{"issue":"14","key":"1166_CR12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/01.aids.0000183519.45137.a6","volume":"19","author":"P Brennan-Benson","year":"2005","unstructured":"Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D (2005) Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 19(14):1541\u20131543","journal-title":"AIDS"},{"issue":"6","key":"1166_CR13","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkl399","volume":"58","author":"G Friedland","year":"2006","unstructured":"Friedland G, Khoo S, Jack C, Lalloo U (2006) Administration of efavirenz (600\u00a0mg\/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 58(6):1299\u20131302. doi: 10.1093\/jac\/dkl399","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1166_CR14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0731-7085(02)00357-6","volume":"30","author":"J Chi","year":"2002","unstructured":"Chi J, Jayewardene AL, Stone JA, Motoya T, Aweeka FT (2002) Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC\/MS\/MS. J Pharm Biomed Anal 30(3):675\u2013684","journal-title":"J Pharm Biomed Anal"},{"key":"1166_CR15","unstructured":"Beal SL SL, Boeckmann A. (1999) NONMEM user\u2019s guide. Division of Pharmacology, University of California, San Francisco"},{"issue":"1","key":"1166_CR16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2003.22","volume":"73","author":"C Csajka","year":"2003","unstructured":"Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73(1):20\u201330. doi: 10.1067\/mcp.2003.22","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1166_CR17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30(5):329\u2013332","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1166_CR18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.00899-08","volume":"53","author":"G Ramachandran","year":"2009","unstructured":"Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S (2009) CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 53(3):863\u2013868. doi: 10.1128\/AAC.00899-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"1166_CR19","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1097\/QAD.0b013e3283189c07","volume":"22","author":"SE Cabrera","year":"2008","unstructured":"Cabrera SE, Cordero M, Iglesias A, Valverde MP, Dominguez-Gil A, Garcia MJ (2008) Efavirenz\u2013rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV\/TBC patients. AIDS 22(18):2549\u20132551. doi: 10.1097\/QAD.0b013e3283189c07","journal-title":"AIDS"},{"issue":"5","key":"1166_CR20","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl357","volume":"58","author":"LF Lopez-Cortes","year":"2006","unstructured":"Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R (2006) Efavirenz trough levels are not associated with virological failure throughout therapy with 800\u00a0mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 58(5):1017\u20131023. doi: 10.1093\/jac\/dkl357","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1166_CR21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2125.2010.03883.x","volume":"71","author":"D Rekic","year":"2011","unstructured":"Rekic D, Roshammar D, Mukonzo J, Ashton M (2011) In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 71(4):536\u2013543. doi: 10.1111\/j.1365-2125.2010.03883.x","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1166_CR22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0b013e31819c33a3","volume":"50","author":"Y Ren","year":"2009","unstructured":"Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM (2009) Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 50(5):439\u2013443. doi: 10.1097\/QAI.0b013e31819c33a3","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1166_CR23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","volume":"14","author":"K Cohen","year":"2009","unstructured":"Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G (2009) Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516\u00a0G > T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 14(5):687\u2013695","journal-title":"Antivir Ther"},{"issue":"5","key":"1166_CR24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","volume":"13","author":"W Stohr","year":"2008","unstructured":"Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S (2008) Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 13(5):675\u2013685","journal-title":"Antivir Ther"},{"issue":"9","key":"1166_CR25","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/0091270008321790","volume":"48","author":"A Kwara","year":"2008","unstructured":"Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH (2008) Pharmacokinetics of efavirenz when co-administered with rifampin in TB\/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 48(9):1032\u20131040. doi: 10.1177\/0091270008321790","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1166_CR26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/QAD.0b013e3283427e05","volume":"25","author":"A Kwara","year":"2011","unstructured":"Kwara A, Lartey M, Sagoe KW, Court MH (2011) Paradoxically elevated efavirenz concentrations in HIV\/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 25(3):388\u2013390. doi: 10.1097\/QAD.0b013e3283427e05","journal-title":"AIDS"},{"issue":"4","key":"1166_CR27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","volume":"61","author":"C Wyen","year":"2008","unstructured":"Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fatkenheuer G, Khoo SH, Egan D, Back DJ, Owen A (2008) Impact of CYP2B6 983\u00a0T > C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 61(4):914\u2013918. doi: 10.1093\/jac\/dkn029","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1166_CR28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2007.02884.x","volume":"64","author":"RK Mehlotra","year":"2007","unstructured":"Mehlotra RK, Bockarie MJ, Zimmerman PA (2007) CYP2B6 983\u00a0T > C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV\/AIDS treatment. Br J Clin Pharmacol 64(3):391\u2013395. doi: 10.1111\/j.1365-2125.2007.02884.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1166_CR29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","volume":"64","author":"C Nyakutira","year":"2008","unstructured":"Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C (2008) High prevalence of the CYP2B6 516\u00a0G\u2013 > T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64(4):357\u2013365. doi: 10.1007\/s00228-007-0412-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1166_CR30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03368.x","volume":"67","author":"A Kwara","year":"2009","unstructured":"Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH (2009) CYP2B6 \u00a9.516\u00a0G-->T) and CYP2A6 (*9B and\/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 67(4):427\u2013436. doi: 10.1111\/j.1365-2125.2009.03368.x","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"1166_CR31","first-page":"2391","volume":"18","author":"DW Haas","year":"2004","unstructured":"Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18(18):2391\u20132400","journal-title":"AIDS"},{"issue":"8","key":"1166_CR32","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2165\/00003088-200544080-00006","volume":"44","author":"BS Kappelhoff","year":"2005","unstructured":"Kappelhoff BS, Huitema AD, Yalvac Z, Prins JM, Mulder JW, Meenhorst PL, Beijnen JH (2005) Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 44(8):849\u2013861","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1166_CR33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5414\/CPP40507","volume":"40","author":"JS Barrett","year":"2002","unstructured":"Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr (2002) Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 40(11):507\u2013519","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"1166_CR34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.47.1.130-137.2003","volume":"47","author":"M Pfister","year":"2003","unstructured":"Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB (2003) Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 47(1):130\u2013137","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1166-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-011-1166-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1166-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T07:42:56Z","timestamp":1686469376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1166-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,23]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1166-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,23]]}}}